冠心宁片对冠心病舒张性心力衰竭患者穿透素3及相关性血细胞分析数值水平的影响

Effect of Guanxinning Tablets on the Numerical Levels of Pentraxin-3 and Related Blood Cell Analysis in Patients with Coronary Heart Disease and Diastolic Heart Failure

目的观察冠心宁片对冠心病舒张性心力衰竭(diastolic heart failure,DHF)患者穿透素3(pentraxin-3,PTX-3)及相关性血细胞分析数值水平的影响。方法选取2018年11月—2019年11月在丽水市中医院就诊的80例冠心病DHF血瘀证患者作为研究对象,采用随机数字表法分为对照组和治疗组,各40例,对照组予以西药治疗,治疗组在对照组基础上加用冠心宁片,连续治疗4周。观察2组中医证候积分、临床疗效、舒张早期的二尖瓣血流峰速度/舒张早期的二尖瓣舒张速度比值(E/E’)、氨基末端B型脑利钠肽前体(N-terminal pro-brain natriuretic peptide,NT-proBNP)、PTX-3及相关性血细胞分析数值水平[包括红细胞分布宽度(redbloodcelldistributionwidth,RDW)、血小板/淋巴细胞比值(plateletto lymphocyte ratio,PLR)、单核细胞/淋巴细胞比值(monocyte to lymphocyte ratio,MLR)、中性粒细胞/淋巴细胞比值(neutrophil tolymphocyteratio,NLR)]的变化,评估冠心病DHF血瘀证患者的治疗效果。结果治疗组总有效率为90.0%,明显优于对照组的77.5%(P<0.05)。治疗前,2组中医证候积分、E/E’、NT-proBNP、PTX-3、RDW、PLR、MLR和NLR比较,差异无统计学意义;治疗后,2组中医证候积分、E/E’、NT-proBNP、PTX-3、RDW、PLR、MLR和NLR明显低于治疗前(P<0.05),且治疗组各指标低于对照组(P<0.05);并且治疗后2组均未见不良反应。结论冠心宁片治疗冠心病DHF患者能够有效改善临床症状,降低中医证候积分、E/E’、NT-pro BNP、PTX-3及相关性血细胞分析数值水平,提高临床疗效。

OBJECTIVE To observe the effect of Guanxinning tablets on the numerical levels of pentraxin-3(PTX-3) and related blood cell analysis in patients with coronary heart disease and diastolic heart failure(DHF). METHODS Eighty patients with blood stasis syndrome of coronary heart disease and DHF who were treated in Lishui Hospital of Traditional Chinese Medicine from November 2018 to November 2019 were selected as the research objects. They were divided into control group and treatment group by a random number table method, each with 40 cases. The control group was treated with western medicine, the treatment group was treated with Guanxinning tablets on the basis of the control group with continuous treatment for 4 weeks. TCM syndrome scores, clinical efficacy, the the ratio of early diastolic mitral inflow velocity to early diastolic velocity of the mitral annulus(E/E’), the numerical levels of N-terminal pro-brain natriuretic peptide(NT-proBNP), PTX-3 and related blood cell analysis such as the red blood cell distribution width(RDW), platelet to lymphocyte ratio(PLR), monocyte to lymphocyte ratio(MLR), neutrophil to lymphocyte ratio(NLR) were observed in the two groups, so as to evaluate the therapeutic effect of patients with blood stasis syndrome of coronary heart disease and DHF. RESULTS After treatment, the total effective rate of the treatment group was 90.0%, which was significantly higher than 75.93% in the control group(P<0.05). Before treatment, TCM syndrome scores, E/E’, NT-pro BNP, PTX-3, RDW, PLR, MLR and NLR were not statistically different in the two groups. After treatment, TCM syndrome scores, E/E’, NT-proBNP, PTX3, RDW, PLR, MLR and NLR were significantly lower in the two groups compared with before treatment(P<0.05), and the indexes in treatment group were significantly lower than those in the control group(P<0.05). There were no adverse reactions in both groups after treatment. CONCLUSION Guanxinning tablets can effectively improve clinical symptoms of patients with coronary heart disease and DHF, can effectively reduce the TCM syndrome scores, E/E’, NT-pro BNP, PTX-3 and related blood cell analysis value level, and enhance the clinical effect.